Literature DB >> 8950074

Contrasting effects of betaxolol and propranolol on Ca(2+)-activated contractions in skinned fibers from canine coronary arteries and ventricular muscles.

Y Kitada1.   

Abstract

The effects of some beta-adrenoceptor antagonists (atenolol, betaxolol, bunitrolol, labetalol, pindolol, and propranolol) on Ca2+ (pCa 5.8)-activated tension development in chemically skinned fibers from canine coronary artery and right ventricular trabeculae were studied. In skinned coronary arteries, Ca(2+)-activated tension development was decreased by betaxolol and propranolol at concentration of more than 10(-5) and 10(-4) M, respectively. The pCa-tension relationships were shifted to the right and down by betaxolol. In contrast, in skinned cardiac muscle Ca(2+)-activated tension development was increased by betaxolol and propranolol at the same range of concentrations as in coronary arteries, with no change in maximum tension. The pCa-tension relation was shifted to the left by betaxolol. Other beta-adrenoceptor antagonists (atenolol, bunitrolol, labetalol, and pindolol) had no effect on Ca(2+)-induced contraction in either muscle type. These results indicate that among beta-adrenoceptor antagonists, only betaxolol and propranolol can directly modulate the Ca2+ sensitivity of myofilaments and have opposite effects on the contractile system in canine cardiac and vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950074     DOI: 10.1007/bf00051000

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  15 in total

1.  Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol.

Authors:  N Satoh; J Suzuki; H Bessho; Y Kitada; A Narimatsu; A Tobe
Journal:  Jpn J Pharmacol       Date:  1990-10

2.  [Antihypertensive effect of betaxolol, a cardioselective beta-adrenoceptor antagonist, in renal hypertensive dogs].

Authors:  H Bessho; J Suzuki; Y Kitada; A Narimatsu; A Tobe
Journal:  Nihon Yakurigaku Zasshi       Date:  1990-06

3.  The beta 1-adrenoceptor antagonist, betaxolol, is not released from the heart of the anaesthetized dog during sympathetic nerve stimulation.

Authors:  N Duval; C R Lee; M T Eon; P Petruzzo; S Z Langer
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

Review 4.  Potential use of third-generation beta-blockers in heart failure.

Authors:  K Chatterjee
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

5.  Contractile proteins: possible targets for the cardiotonic action of MCI-154, a novel cardiotonic agent?

Authors:  Y Kitada; A Narimatsu; N Matsumura; M Endo
Journal:  Eur J Pharmacol       Date:  1987-02-10       Impact factor: 4.432

6.  Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells.

Authors:  A Fabiato; F Fabiato
Journal:  J Physiol (Paris)       Date:  1979

7.  Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.

Authors:  I Edes; E Kiss; Y Kitada; F M Powers; J G Papp; E G Kranias; R J Solaro
Journal:  Circ Res       Date:  1995-07       Impact factor: 17.367

8.  Vascular effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, in isolated rat arteries.

Authors:  H Bessho; J Suzuki; A Tobe
Journal:  Jpn J Pharmacol       Date:  1991-03

9.  Effects of (+)-propranolol on intracellular mechanisms of contraction in striated muscle of the rabbit.

Authors:  J Y Su; D A Malencik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

10.  Stimulation of cardiac myofilament force, ATPase activity and troponin C Ca++ binding by bepridil.

Authors:  R J Solaro; P Bousquet; J D Johnson
Journal:  J Pharmacol Exp Ther       Date:  1986-08       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.